FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1630202375> ?p ?o ?g. }

• W1630202375 endingPage "210" @default.
• W1630202375 startingPage "195" @default.
• W1630202375 abstract "The aim of the study was to evaluate the potential influence of ranibizumab and bevacizumab on platelet activation and aggregation, which are critical processes in the pathogenesis of arterial thromboembolic events (ATEs).For the assessment of platelet function, flow cytometry and aggregometry were employed. Platelets were isolated from healthy volunteers and exposed to ranibizumab (1 mg/ml and 150 ng/ml) and bevacizumab (2.5 mg/ml and 3 μg/ml) or their solvents for 10 and 30 min prior to the addition of TRAP (25 μM), PAR-4-AP (25 μM) or thrombin (0.02 U/ml). The surface expression of activated GP IIb/IIIa, P-selectin (CD62P) and platelet-bound stromal cell-derived factor-1 (SDF-1) was measured on resting (nonactivated) and activated platelets by flow cytometry. The platelet aggregation capacity was examined using light transmission aggregometry.The expression of surface activation markers did not differ significantly between nonstimulated and TRAP-, PAR-4-AP- or thrombin-activated platelets after incubating with ranibizumab. However, GP IIb/IIIa, CD62P and SDF-1 were significantly downregulated in PAR-4-AP- and thrombin-activated platelets after exposure to bevacizumab 2.5 mg/ml. In addition, ranibizumab- and bevacizumab-FITC were significantly increased in all activated platelets. No significant differences were observed in the aggregation of activated platelets after incubation with ranibizumab or bevacizumab.All ranibizumab concentrations as well as the bevacizumab concentration of 3 μg/ml had no influence on platelet activation and aggregation. Therefore, this in vitro study did not show any relationship between the exposition of activated platelets to ranibizumab or bevacizumab and the development of ATEs. However, the highest level of bevacizumab interfered with platelet activation, leading to downregulation of platelet activation markers. This observation might explain why the systemic treatment with high-dose bevacizumab could be associated with an increased risk of bleeding. Regarding the use of lower intravitreal dosages, further research should focus on the complex interactions between platelets and other cells, such as endothelial cells, which might stronger relate to a potentially increased risk of ATEs and depend on systemic vascular endothelial growth factor levels. Facing the different activation profiles, the diverse effects of the drugs on the cellular level have to be critically scrutinized for their clinical relevance." @default.
• W1630202375 created "2016-06-24" @default.
• W1630202375 creator A5013763793 @default.
• W1630202375 creator A5019337131 @default.
• W1630202375 creator A5066082619 @default.
• W1630202375 creator A5069429479 @default.
• W1630202375 creator A5075842464 @default.
• W1630202375 creator A5076551740 @default.
• W1630202375 creator A5079535900 @default.
• W1630202375 creator A5081342175 @default.
• W1630202375 date "2015-01-01" @default.
• W1630202375 modified "2023-09-25" @default.
• W1630202375 title "Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile" @default.
• W1630202375 cites W1500728559 @default.
• W1630202375 cites W1539571840 @default.
• W1630202375 cites W1588197618 @default.
• W1630202375 cites W1964104983 @default.
• W1630202375 cites W1966486839 @default.
• W1630202375 cites W1972242350 @default.
• W1630202375 cites W1987174800 @default.
• W1630202375 cites W1991843154 @default.
• W1630202375 cites W1992528831 @default.
• W1630202375 cites W1996044788 @default.
• W1630202375 cites W2004196006 @default.
• W1630202375 cites W2005385371 @default.
• W1630202375 cites W2013865180 @default.
• W1630202375 cites W2017314392 @default.
• W1630202375 cites W2017627757 @default.
• W1630202375 cites W2018777580 @default.
• W1630202375 cites W2027538443 @default.
• W1630202375 cites W2034029819 @default.
• W1630202375 cites W2034893493 @default.
• W1630202375 cites W2036187245 @default.
• W1630202375 cites W2037978728 @default.
• W1630202375 cites W2039446733 @default.
• W1630202375 cites W2039936409 @default.
• W1630202375 cites W2058217708 @default.
• W1630202375 cites W2058458259 @default.
• W1630202375 cites W2071461268 @default.
• W1630202375 cites W2072011053 @default.
• W1630202375 cites W2083058564 @default.
• W1630202375 cites W2091407629 @default.
• W1630202375 cites W2093044616 @default.
• W1630202375 cites W2095251825 @default.
• W1630202375 cites W2096547439 @default.
• W1630202375 cites W2104569020 @default.
• W1630202375 cites W2111053501 @default.
• W1630202375 cites W2119409308 @default.
• W1630202375 cites W2121785313 @default.
• W1630202375 cites W2124415048 @default.
• W1630202375 cites W2129349255 @default.
• W1630202375 cites W2130569605 @default.
• W1630202375 cites W2140018458 @default.
• W1630202375 cites W2140181275 @default.
• W1630202375 cites W2141508695 @default.
• W1630202375 cites W2142693543 @default.
• W1630202375 cites W2146673937 @default.
• W1630202375 cites W2152887453 @default.
• W1630202375 cites W2154073405 @default.
• W1630202375 cites W2155560850 @default.
• W1630202375 cites W2157848273 @default.
• W1630202375 cites W2162944147 @default.
• W1630202375 cites W2165733162 @default.
• W1630202375 cites W2493651413 @default.
• W1630202375 doi "https://doi.org/10.1159/000437057" @default.
• W1630202375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26305017" @default.
• W1630202375 hasPublicationYear "2015" @default.
• W1630202375 type Work @default.
• W1630202375 sameAs 1630202375 @default.
• W1630202375 citedByCount "9" @default.
• W1630202375 countsByYear W16302023752015 @default.
• W1630202375 countsByYear W16302023752018 @default.
• W1630202375 countsByYear W16302023752020 @default.
• W1630202375 countsByYear W16302023752021 @default.
• W1630202375 countsByYear W16302023752023 @default.
• W1630202375 crossrefType "journal-article" @default.
• W1630202375 hasAuthorship W1630202375A5013763793 @default.
• W1630202375 hasAuthorship W1630202375A5019337131 @default.
• W1630202375 hasAuthorship W1630202375A5066082619 @default.
• W1630202375 hasAuthorship W1630202375A5069429479 @default.
• W1630202375 hasAuthorship W1630202375A5075842464 @default.
• W1630202375 hasAuthorship W1630202375A5076551740 @default.
• W1630202375 hasAuthorship W1630202375A5079535900 @default.
• W1630202375 hasAuthorship W1630202375A5081342175 @default.
• W1630202375 hasConcept C126322002 @default.
• W1630202375 hasConcept C185592680 @default.
• W1630202375 hasConcept C203014093 @default.
• W1630202375 hasConcept C2776694085 @default.
• W1630202375 hasConcept C2777292125 @default.
• W1630202375 hasConcept C2777802072 @default.
• W1630202375 hasConcept C2781100027 @default.
• W1630202375 hasConcept C3018697912 @default.
• W1630202375 hasConcept C553184892 @default.
• W1630202375 hasConcept C71924100 @default.
• W1630202375 hasConcept C89560881 @default.
• W1630202375 hasConcept C98274493 @default.
• W1630202375 hasConceptScore W1630202375C126322002 @default.
• W1630202375 hasConceptScore W1630202375C185592680 @default.

• next